Evaluation of Efficacy and Safety of AGP on Immune Enhancement

An 8 Week, Randomized, Double-blind, Placebo-controlled Clinical Trial of AGP on Immune Enhancing Effects

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03330392

Enrollment

Registered

2017-11-06

Start date

2017-07-01

Completion date

2017-10-27

Last updated

2017-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune Function

Brief summary

The researchers investigated the immune enhancing effects of AGP for Korean participants.

Detailed description

The aim of the study is to investigate the effects of AGP on immune enhancement based on 8 week, randomized, double-blind, placebo-controlled clinical trial.

Interventions

DIETARY_SUPPLEMENTAGP

take two tablets per day (500 mg/day) for 8 weeks

DIETARY_SUPPLEMENTPlacebo

take two tablets per day (500 mg/day) for 8 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* The levels of white blood cells within range 3x10\^3/μL\ 8x10\^3/μL * have had at least two cold in the last 12 months.

Exclusion criteria

* subjects with BMI\<18.5 kg/m\^2 * subjects taking medications such as immune related drug or functional foods * history of disease that could interfere with the test products or impede their absorption * pregnant or lactating women and heavy smokers. * being judged by the responsible physician of the local study center as unfit to participate in the study

Design outcomes

Primary

Measure	Time frame	Description
Natural killer cell activity	0 week, 8 week	Changes of NK cell activity were assessed before and after the intervention.

Secondary

Measure	Time frame	Description
Interleukin-6	0 week, 8 week	Changes of IL-6 were assessed before and after the intervention.
Interleukin-12 (IL-12)	0 week, 8 week	Changes of IL-12 were assessed before and after the intervention.
Interleukin-1β	0 week, 8 week	Changes of IL-1β were assessed before and after the intervention.
Tumor necrosis factor-α (TNF-α)	0 week, 8 week	Changes of TNF-α were assessed before and after the intervention.
Changes of White blood cell (WBC)	0 week, 8 week	Changes of WBC were assessed before and after the intervention.
Interferon-γ (IFN-γ)	0 week, 8 week	Changes of IFN-γ were assessed before and after the intervention.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026